| 33.13 -1.08 (-3.16%) | 09-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 45.4 |
1-year : | 49.88 |
| Resists | First : | 38.87 |
Second : | 42.7 |
| Pivot price | 36.48 |
|||
| Supports | First : | 32.66 |
Second : | 27.18 |
| MAs | MA(5) : | 33.94 |
MA(20) : | 37.53 |
| MA(100) : | 38.59 |
MA(250) : | 40.99 |
|
| MACD | MACD : | -1.7 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 10  |
D(3) : | 7.7 |
| RSI | RSI(14): 30.6 |
|||
| 52-week | High : | 54.84 | Low : | 28.54 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ HROW ] has closed above bottom band by 6.4%. Bollinger Bands are 5.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 34.78 - 34.98 | 34.98 - 35.13 |
| Low: | 32.09 - 32.36 | 32.36 - 32.57 |
| Close: | 32.74 - 33.13 | 33.13 - 33.45 |
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
Tue, 04 Aug 2026
Harrow, Inc. (HROW) Stock Analysis: Exploring the 73% Upside Potential for This Eyecare Innovator - DirectorsTalk Interviews
Tue, 21 Jul 2026
Harrow, Inc. (HROW) Stock Analysis: Strong Buy Ratings and 52% Potential Upside Drive Investor Interest - DirectorsTalk Interviews
Mon, 20 Jul 2026
Harrow presents studies on eye care products at medical meeting - Investing.com
Tue, 26 May 2026
HROW - Finviz
Mon, 11 May 2026
HARROW HEALTH ($HROW) Releases Q1 2026 Earnings - Quiver Quantitative
Mon, 01 Dec 2025
Harrow: Vevye Replaces Xiidra On Tier 1 Formulary At CVS (NASDAQ:HROW) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 37 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 15.3 (%) |
| Held by Institutions | 58.5 (%) |
| Shares Short | 6,360 (K) |
| Shares Short P.Month | 6,840 (K) |
| EPS | -1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.4 |
| Profit Margin | -13.6 % |
| Operating Margin | -15.6 % |
| Return on Assets (ttm) | -0.5 % |
| Return on Equity (ttm) | -116.1 % |
| Qtrly Rev. Growth | 10.8 % |
| Gross Profit (p.s.) | 5.38 |
| Sales Per Share | 7.35 |
| EBITDA (p.s.) | 0.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 6 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -33.47 |
| PEG Ratio | 0 |
| Price to Book value | 80.8 |
| Price to Sales | 4.5 |
| Price to Cash Flow | 198.72 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|